Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 3(63), 2019

DOI: 10.1128/aac.02164-18

Links

Tools

Export citation

Search in Google Scholar

Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection

Journal article published in 2019 by Sean Wasserman ORCID, Paolo Denti ORCID, James C. M. Brust, Mahmoud Abdelwahab, Siphokazi Hlungulu, Lubbe Wiesner ORCID, Jennifer Norman, Frederick A. Sirgel, Robin M. Warren, Aliasgar Esmail, Keertan Dheda, Neel R. Gandhi ORCID, Graeme Meintjes, Gary Maartens
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The World Health Organization (WHO) recently recommended that linezolid be prioritized in treatment regimens for drug-resistant tuberculosis (TB), but there are limited data on its pharmacokinetics (PK) in patients with this disease. We conducted an observational study to explore covariate effects on linezolid PK and to estimate the probability of PK/pharmacodynamic target attainment in South African patients with drug-resistant TB.